Opinion|Videos|June 25, 2024
Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices
Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What clinical factors do you consider for patients with R/R DLBCL who are primary refractory or experience early relapse in determining transplant eligibility?
- When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
- Are most community oncologists referring to CAR T-cell centers or keeping their patients?
- How early are patients being referred to your center (eg, second-line, third-line)?
- When do you initiate the collection/production process?
- What is the primary impetus for early referral?
- When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
3
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5